Autologous Stem Cell and Non-Stem Cell Based Therapies Market - Global Forecast To 2029
| 出版年月 | 2024年6月 |
| ページ数 | 295 |
| 図表数 | 375 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The autologous stem cell & non-stem cell therapies market is projected to reach USD 22.2 billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 32.3% during the forecast period.
自己幹細胞および非幹細胞療法市場は、予測期間中のCAGR 32.3%で、2024年の55億米ドルから2029年までに222億米ドルに達すると予測されています。
The growth of this market is driven by several factors such as the growing regulatory approvals for autologous CAR T cell-based therapies, increasing R&D investments for the development of autologous cell therapies, and an increase in the demand for personalized medicines.
“The autologous stem cell & non-stem cell therapies market growth for Autologous non-stem cell therapies can be attributed to the increasing number of cancer cases leading to increased demand for substantial treatment option.”
The autologous stem cell & non-stem cell therapies market, based on type segment is further segmented into autologous stem cell therapies and autologous non-stem cell therapies. The autologous non-stem cell therapies sub-segment is further divided into CAR T cell therapies, Tumor Infiltrating Lymphocyte (TIL), and other therapies (of skin grafts, others). The autologous non-stem cell therapies hold the dominant share due to the rise in global cancer cases accelerating the demand for the development of effective cancer treatment solutions such as autologous non-stem-cell-based therapies, which are increasingly valued in the market due to the rising number of regulatory approvals for these therapies and growing number of cancer patients seeking viable treatment alternatives.
“By Indications, the cancer indication subsegment accounted for the largest share of the autologous stem cell & non-stem cell therapies market in 2023.”
The indication segment is further segmented into cancer indications and non-cancer indications. In 2023, the cancer indications subsegment accounted for the largest share of the indication segment due to the rising number of global cancer cases, and a growing demand for the development of effective and efficient cancer therapeutics such as autologous CAR T cell therapies, that are shown to be effective for treating various forms of cancer such as multiple myeloma and various types of lymphoma.
“North American region is expected to register the highest CAGR in the autologous stem cell & non-stem cell therapies market.”
The market for autologous stem cell & non-stem cell therapies in North America is estimated to grow at the highest rate during the forecast period. The rising academic and organizational interest in autologous stem cell and non-stem cell-based research, complemented by the North American healthcare sector’s expansion and the rising approvals and utilization of autologous stem cell and non-stem cell-based therapies for cancer and other chronic diseases are factors that will aid the market growth in North America. North America also has an established pharmaceutical manufacturing infrastructure and the presence of prominent players in the autologous stem cell & non-stem cell therapies market such as Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US) among others which further supports the leadership position of this region.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70% and Demand Side – 30%
• By Designation: C Level Executives- 55%, CXOs, and Director level – 20%, and Others- 25%
• By Region: North America -50%, Europe – 20%, Asia-Pacific -20%, RoW -10%
List of Companies Profiled in the Report
• Gilead Sciences, Inc. (US)
• Bristol-Myers Squibb Company (US)
• Johnson & Johnson (US)
• Vericel Corporation (US)
• Novartis AG (Switzerland)
• JW (Cayman) Therapeutics Co. Ltd (China)
• APAC Biotech (India)
• Regrow Biosciences Pvt Ltd. (India)
• Healiva SA (Switzerland)
Note: The above list is inexhaustive
Research Coverage:
This report provides a detailed picture of the autologous stem cell & non-stem cell therapies market. It aims to estimate the market’s size and future growth potential across different segments such as the type, indication, source, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, key market strategies, funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the autologous stem cell & non-stem cell therapies market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall autologous stem cell & non-stem cell therapies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (e.g., increasing government approvals for various autologous cell-based therapies, increasing investments and funding towards the development of autologous cell-based therapies and the growing number of clinical trials involving autologous stem and non-stem cells), restraints (e.g., uptake of allogeneic cell-based therapies as substitutes), opportunities (e.g, outsourcing manufacturing of cell therapy and focus on closed automated systems), and challenges (e.g, regulatory complications and reimbursement challenges and issues in scalable manufacturing) are influencing the growth of the autologous stem cell & non-stem cell therapies market.
• Product Approvals: Detailed insights on newly approved products of the autologous stem cell & non-stem cell therapies market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the autologous stem cell & non-stem cell therapies market across varied regions.
• Market Diversification: Exhaustive information about new products, recent developments, and investments in the autologous stem cell & non-stem cell therapies market.
• Pipeline Analysis: Comprehensive information about products under clinical trials.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players including Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Vericel Corporation (US), Novartis AG (Switzerland), JW (Cayman) Therapeutics Co. Ltd (China), Iovance Biotherapeutics, Inc. (US), APAC Biotech (India), Regrow Biosciences Pvt Ltd. (India), healiva SA (Switzerland), Green Cross Holdings Co., Ltd. (GC Cell) (Republic of Korea)), Sanpower Group Co., Ltd. (Dendreon Pharmaceuticals Llc. (China), Tegoscience (South Korea), ImmunoACT (India), CARsgen Therapeutics Holdings Limited (China), IASO Biotherapeutics (China), Pharmicell Co., Ltd (South Korea), Anterogen.Co.,Ltd. (South Korea) among others offering autologous stem cell & non-stem cell-based therapeutic products.
Table of Contents
1 INTRODUCTION 43
1.1 STUDY OBJECTIVES 43
1.2 MARKET DEFINITION 43
1.2.1 INCLUSIONS & EXCLUSIONS 44
1.3 MARKET SCOPE 44
1.3.1 MARKET SEGMENTATION 44
1.3.2 REGIONAL SEGMENTATION 45
FIGURE 1 REGIONS COVERED 45
1.3.3 YEARS CONSIDERED 45
1.3.4 CURRENCY CONSIDERED 46
1.4 STAKEHOLDERS 46
1.5 SUMMARY OF CHANGES 46
1.6 RECESSION IMPACT 47
2 RESEARCH METHODOLOGY 48
2.1 RESEARCH DATA 48
FIGURE 2 RESEARCH DESIGN 48
2.1.1 SECONDARY DATA 49
2.1.2 PRIMARY DATA 50
FIGURE 3 BREAKDOWN OF PRIMARIES: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 50
2.2 MARKET SIZE ESTIMATION 51
FIGURE 4 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS, 2023 51
FIGURE 5 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: REVENUE SHARE ANALYSIS, 2023 52
FIGURE 6 GILEAD SCIENCES, INC.: REVENUE SHARE ANALYSIS, 2023 52
2.3 PRIMARY INSIGHTS 54
FIGURE 7 VALIDATION FROM PRIMARY EXPERTS 54
2.3.1 SEGMENTAL ASSESSMENT 54
FIGURE 8 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 54
2.4 GROWTH FORECAST 55
FIGURE 9 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: CAGR PROJECTIONS (2024–2029) 56
FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
2.5 VOLUME ESTIMATION 57
2.6 MARKET BREAKDOWN & DATA TRIANGULATION 58
FIGURE 11 DATA TRIANGULATION METHODOLOGY 58
2.7 STUDY ASSUMPTIONS 59
2.8 RISK ANALYSIS 59
TABLE 1 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: RISK ASSESSMENT ANALYSIS 59
2.9 RECESSION IMPACT ANALYSIS 59
TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH) 59
3 EXECUTIVE SUMMARY 61
FIGURE 12 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 61
FIGURE 13 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION) 62
FIGURE 14 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION) 62
FIGURE 15 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2024−2029 63
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET 64
4 PREMIUM INSIGHTS 65
4.1 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET OVERVIEW 65
FIGURE 17 RISING REGULATORY APPROVALS FOR CAR T-CELL THERAPIES TO DRIVE MARKET 65
4.2 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE AND COUNTRY (2023) 66
FIGURE 18 AUTOLOGOUS NON-STEM CELL THERAPIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 66
4.3 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY SOURCE, 2024 VS. 2029 66
FIGURE 19 T-CELLS SOURCE SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 66
4.4 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY INDICATION, 2023 67
FIGURE 20 CANCER INDICATION SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023 67
4.5 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 67
FIGURE 21 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 67
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
FIGURE 22 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 68
TABLE 3 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: IMPACT ANALYSIS 69
5.2.1 DRIVERS 69
5.2.1.1 Rising approvals for CAR T-cell therapies 69
TABLE 4 APPROVED AUTOLOGOUS CAR T-CELL THERAPIES 70
5.2.1.2 Increasing R&D investments in autologous therapeutics 71
5.2.1.3 Increasing demand for personalized medicine 71
5.2.2 RESTRAINTS 72
5.2.2.1 Uptake of allogeneic cell-based therapies as substitutes 72
5.2.3 OPPORTUNITIES 73
5.2.3.1 Rising outsourcing of manufacturing activities 73
5.2.3.2 Adoption of closed automated systems 73
5.2.4 CHALLENGES 74
5.2.4.1 Stringent regulatory guidelines and reimbursement challenges 74
5.2.4.2 Issues associated with scalable manufacturing 74
5.3 SUPPLY CHAIN ANALYSIS 75
FIGURE 23 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES 76
5.4 TECHNOLOGY ANALYSIS 76
5.4.1 KEY TECHNOLOGIES 76
5.4.1.1 Genome editing 76
5.4.1.2 Synthetic biology 77
5.4.2 COMPLEMENTARY TECHNOLOGIES 77
5.4.2.1 Process analytical technology (PAT) 77
5.4.2.2 Point-of-care manufacturing 77
5.5 VALUE CHAIN ANALYSIS 78
FIGURE 24 VALUE CHAIN ANALYSIS—MAXIMUM VALUE IS ADDED DURING THERAPY MANUFACTURING PHASE 79
5.6 PRICING ANALYSIS 80
TABLE 5 AVERAGE SELLING PRICE FOR LEADING AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPEUTIC DRUGS 80
TABLE 6 AVERAGE SELLING PRICE FOR MAJOR AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPEUTIC DRUGS, BY REGION 81
5.7 ECOSYSTEM ANALYSIS 81
5.7.1 ROLE IN ECOSYSTEM 82
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83
FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPY MARKET MANUFACTURERS 83
5.9 PATENT ANALYSIS 84
5.9.1 PATENT ANALYSIS: AUTOLOGOUS CAR-T THERAPIES 84
FIGURE 27 PATENT APPLICATIONS FOR AUTOLOGOUS CAR-T THERAPIES, JANUARY 2013–OCTOBER 2023 84
5.9.2 PATENT ANALYSIS: TIL THERAPY 85
FIGURE 28 PATENT APPLICATIONS FOR TIL THERAPIES, JANUARY 2013–OCTOBER 2023 85
5.10 KEY CONFERENCES & EVENTS, 2024−2025 86
TABLE 7 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: LIST OF CONFERENCES & EVENTS 86
5.11 REGULATORY LANDSCAPE 88
5.11.1 REGULATORY ANALYSIS 88
5.11.2 NORTH AMERICA 88
5.11.2.1 US 88
5.11.2.2 Canada 88
5.11.3 EUROPE 89
5.11.3.1 Germany 89
5.11.3.2 UK 89
5.11.3.3 Rest of Europe 90
5.11.4 ASIA PACIFIC 90
5.11.4.1 China 90
5.11.4.2 Japan 91
5.11.4.3 South Korea 91
5.11.4.4 Australia 92
5.11.4.5 Rest of Asia Pacific 92
5.11.5 REGULATORY BODIES AND ORGANIZATIONS 92
TABLE 8 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 9 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 10 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 11 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 12 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
5.12 PORTER’S FIVE FORCES ANALYSIS 96
FIGURE 29 AUTOLOGOUS STEM CELL & NON-STEM CELL MARKET: PORTER’S FIVE FORCE ANALYSIS 96
TABLE 13 PORTER’S FIVE FORCES ANALYSIS 96
5.12.1 DEGREE OF COMPETITION 97
5.12.2 BARGAINING POWER OF SUPPLIERS 97
5.12.3 BARGAINING POWER OF BUYERS 97
5.12.4 THREAT OF SUBSTITUTES 97
5.12.5 THREAT OF NEW ENTRANTS 98
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 98
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 98
5.14 KEY BUYING CRITERIA 99
5.14.1 BUYING CRITERIA OF END USERS FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPEUTIC PRODUCTS 99
5.14.2 BUYING CRITERIA FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPEUTIC PRODUCTS, BY END USER 99
5.15 INVESTMENT AND FUNDING SCENARIO 100
5.16 CASE STUDY ANALYSIS 102
5.16.1 CASE STUDY 1 102
5.16.1.1 Comparative Analysis of Cupistem Efficacy in Treatment of Crohn’s Perianal Fistulas 102
5.16.2 CASE STUDY 2 102
5.16.2.1 Evaluating Lenzumestrocel (Neuronata-R) in Amyotrophic Lateral Sclerosis: The ALSUMMIT Phase III Trial Protocol 102
5.16.3 CASE STUDY 3 103
5.16.3.1 Stemirac Stem Cell Therapy for Traumatic Spinal Cord Injury 103
5.16.4 CASE STUDY 4 103
5.16.4.1 Efficacy and Safety of Holoclar in Limbal Stem Cell Deficiency 103
6 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE 104
6.1 INTRODUCTION 105
TABLE 14 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 105
TABLE 15 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (UNITS) 105
6.2 AUTOLOGOUS STEM CELL THERAPIES 105
6.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 105
TABLE 16 AUTOLOGOUS STEM CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION) 106
TABLE 17 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 18 EUROPE: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 19 ASIA PACIFIC: AUTOLOGOUS STEM CELL MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 20 LATIN AMERICA: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 21 MIDDLE EAST: AUTOLOGOUS STEM CELL MARKET, BY REGION, 2022–2029 (USD MILLION) 108
TABLE 22 GCC COUNTRIES: AUTOLOGOUS STEM CELL MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 108
6.3 AUTOLOGOUS NON-STEM CELL THERAPIES 109
TABLE 23 AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 109
TABLE 24 AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION) 109
TABLE 25 NORTH AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 26 EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 27 ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 111
6.4 CAR T-CELL THERAPIES 111
6.4.1 GROWING APPROVAL OF AUTOLOGOUS CAR T-CELL THERAPIES TO BOOST GROWTH 111
TABLE 28 CAR T-CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION) 112
TABLE 29 NORTH AMERICA: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 30 EUROPE: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 31 ASIA PACIFIC: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 113
6.5 TUMOR-INFILTRATING LYMPHOCYTES (TILS) 113
6.5.1 EMERGING POTENTIAL OF TIL IN CANCER TREATMENT TO BOOST DEMAND 113
TABLE 32 TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY REGION, 2022–2029 (USD MILLION) 114
TABLE 33 NORTH AMERICA: TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 114
7 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION 115
7.1 INTRODUCTION 116
TABLE 34 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 116
7.2 CANCER INDICATION 116
7.2.1 RISING INCIDENCE OF CANCER AND GROWING DEMAND FOR THERAPEUTICS TO DRIVE MARKET 116
TABLE 35 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKEY FOR CANCER INDICATIONS, BY REGION, 2022–2029 (USD MILLION) 117
TABLE 36 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 37 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 38 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 118
7.3 MUSCULOSKELETAL INDICATION 118
7.3.1 GROWING INCIDENCE OF OSTEOARTHRITIS TO DRIVE MARKET 118
TABLE 39 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY REGION, 2022–2029 (USD MILLION) 119
TABLE 40 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 41 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 42 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 43 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 44 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY REGION, 2022–2029 (USD MILLION) 121
TABLE 45 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 121
7.4 DERMATOLOGY INDICATION 122
7.4.1 INCREASING PREVALENCE OF SKIN DISORDERS TO SUPPORT MARKET GROWTH 122
TABLE 46 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY REGION, 2022–2029 (USD MILLION) 122
TABLE 47 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 48 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 49 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 50 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 51 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY REGION, 2022–2029 (USD MILLION) 124
TABLE 52 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 124
7.5 OTHER INDICATIONS 125
TABLE 53 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2029 (USD MILLION) 125
TABLE 54 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 125
TABLE 55 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 56 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 57 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 58 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2029 (USD MILLION) 127
TABLE 59 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 127
8 AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPIES MARKET, BY SOURCE 128
8.1 INTRODUCTION 128
TABLE 60 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 128
8.2 T-CELLS 128
8.2.1 GROWING ADOPTION OF CAR T-CELL THERAPIES TO DRIVE MARKET 128
TABLE 61 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY REGION, 2022–2029 (USD MILLION) 129
TABLE 62 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 63 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 64 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 130
8.3 MESENCHYMAL STEM CELLS 131
8.3.1 HIGH UPTAKE IN DEVELOPMENT OF AUTOLOGOUS THERAPIES TO SUPPORT MARKET GROWTH 131
TABLE 65 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY REGION, 2022–2029 (USD MILLION) 131
TABLE 66 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 67 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 68 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 69 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 70 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY REGION, 2022–2029 (USD MILLION) 133
TABLE 71 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 134
9 AUTOLOGOUS STEM-CELL & NON-STEM CELL THERAPIES MARKET, BY END USER 135
9.1 INTRODUCTION 136
TABLE 72 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 136
9.2 HOSPITALS AND CLINICS 136
9.2.1 ABILITY TO UNDERTAKE APHERESIS PROCEDURES WITH ADVANCED HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET 136
TABLE 73 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022–2029 (USD MILLION) 137
TABLE 74 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 75 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 76 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 77 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 78 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022–2029 (USD MILLION) 139
TABLE 79 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 139
9.3 LONG-TERM CARE FACILITIES 140
9.3.1 RISING INCIDENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH 140
TABLE 80 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION) 140
TABLE 81 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 82 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 83 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 84 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 85 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION) 142
TABLE 86 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 142
9.4 SPECIALTY CARE CENTERS 143
9.4.1 GROWING PREFERENCE FOR PERSONALIZED MEDICINE TO BOOST DEMAND 143
TABLE 87 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY REGION, 2022–2029 (USD MILLION) 143
TABLE 88 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 89 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 90 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 91 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 92 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY REGION, 2022–2029 (USD MILLION) 145
TABLE 93 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 145
10 AUTOLOGOUS STEM CELL AND NON-STEM STEM CELL THERAPIES MARKET, BY REGION 146
10.1 INTRODUCTION 147
TABLE 94 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION) 147
10.2 NORTH AMERICA 147
10.2.1 NORTH AMERICA: RECESSION IMPACT 147
FIGURE 31 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SNAPSHOT 148
TABLE 95 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 96 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 149
TABLE 97 NORTH AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 149
TABLE 98 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 150
TABLE 99 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 150
TABLE 100 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 150
10.2.2 US 151
10.2.2.1 Rising R&D activities for stem cell therapies to drive market 151
TABLE 101 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 151
TABLE 102 US: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 152
TABLE 103 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 152
TABLE 104 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 152
TABLE 105 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 153
10.2.3 CANADA 153
10.2.3.1 Rising government initiatives for regenerative medicine research to drive market 153
TABLE 106 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 154
TABLE 107 CANADA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 154
TABLE 108 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 154
TABLE 109 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 155
TABLE 110 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 155
10.3 EUROPE 155
10.3.1 EUROPE: RECESSION IMPACT 156
TABLE 111 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 112 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 157
TABLE 113 EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 157
TABLE 114 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 157
TABLE 115 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 158
TABLE 116 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 158
10.3.2 GERMANY 158
10.3.2.1 Rising focus on clinical research to drive market 158
TABLE 117 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 159
TABLE 118 GERMANY: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 159
TABLE 119 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 159
TABLE 120 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 160
TABLE 121 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 160
10.3.3 UK 160
10.3.3.1 Rising technological advancements in automation to drive market 160
TABLE 122 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 161
TABLE 123 UK: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 161
TABLE 124 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 162
TABLE 125 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 162
TABLE 126 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 162
10.3.4 FRANCE 163
10.3.4.1 Growing focus on cell & gene therapy initiatives to boost demand 163
TABLE 127 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 128 FRANCE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 129 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 164
TABLE 130 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 164
TABLE 131 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 164
10.3.5 ITALY 165
10.3.5.1 Growth in biotech sector to drive market 165
TABLE 132 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 133 ITALY: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 134 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 166
TABLE 135 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 166
TABLE 136 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 166
10.3.6 SPAIN 167
10.3.6.1 Rising focus on stem cell banking to support market growth 167
TABLE 137 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 138 SPAIN: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 139 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 168
TABLE 140 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 168
TABLE 141 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 168
10.3.7 REST OF EUROPE 169
TABLE 142 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 143 REST OF EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 144 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 170
TABLE 145 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 170
TABLE 146 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 170
10.4 ASIA PACIFIC 171
10.4.1 ASIA PACIFIC: RECESSION IMPACT 171
FIGURE 32 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SNAPSHOT 172
TABLE 147 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 148 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 149 ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 150 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 174
TABLE 151 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 174
TABLE 152 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 174
10.4.2 JAPAN 175
10.4.2.1 Increasing product approvals to drive market 175
TABLE 153 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 175
TABLE 154 JAPAN: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 176
TABLE 155 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 176
TABLE 156 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 176
TABLE 157 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 177
10.4.3 CHINA 177
10.4.3.1 Rising number of CAR T-cell clinical trials to support market growth 177
TABLE 158 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 159 CHINA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 160 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 178
TABLE 161 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 179
TABLE 162 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 179
10.4.4 INDIA 179
10.4.4.1 Rising incidence of cancer and growing focus on product commercialization to boost demand 179
TABLE 163 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 180
TABLE 164 INDIA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 180
TABLE 165 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 180
TABLE 166 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 181
TABLE 167 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 181
10.4.5 SOUTH KOREA 181
10.4.5.1 Rising growth in biopharmaceutical industry to drive market 181
TABLE 168 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 169 SOUTH KOREA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 170 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 183
TABLE 171 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 183
TABLE 172 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 183
10.4.6 REST OF ASIA PACIFIC 184
TABLE 173 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 174 REST OF ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 175 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 185
TABLE 176 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 185
TABLE 177 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 185
10.5 LATIN AMERICA 186
10.5.1 LATIN AMERICA: RECESSION IMPACT 186
TABLE 178 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 179 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 180 LATIN AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 181 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 187
TABLE 182 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 188
TABLE 183 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 188
10.5.2 BRAZIL 188
10.5.2.1 High expenditure on healthcare to support market growth 188
TABLE 184 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 185 BRAZIL: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 186 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 190
TABLE 187 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 190
TABLE 188 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 190
10.5.3 MEXICO 191
10.5.3.1 Low operating costs to support market growth 191
TABLE 189 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 191
TABLE 190 MEXICO: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 191
TABLE 191 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 192
TABLE 192 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 192
TABLE 193 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 192
10.5.4 ARGENTINA 193
10.5.4.1 Funding for stem cell research to drive market 193
TABLE 194 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 195 ARGENTINA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 196 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 194
TABLE 197 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 194
TABLE 198 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 195
10.5.5 REST OF LATIN AMERICA 195
TABLE 199 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 195
TABLE 200 REST OF LATIN AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION) 196
TABLE 201 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 196
TABLE 202 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 196
TABLE 203 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 197
10.6 MIDDLE EAST 197
10.6.1 MIDDLE EAST: RECESSION IMPACT 197
TABLE 204 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY REGION, 2022–2029 (USD MILLION) 198
TABLE 205 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 198
TABLE 206 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 207 MIDDLE EAST: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 208 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 199
TABLE 209 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 199
TABLE 210 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 200
10.6.2 GCC COUNTRIES 200
TABLE 211 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 212 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 201
TABLE 213 GCC COUNTRIES: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 201
TABLE 214 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 201
TABLE 215 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 202
TABLE 216 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 202
10.6.2.1 Kingdom of Saudi Arabia (KSA) 202
10.6.2.1.1 Growing demand for novel therapeutics to boost demand 202
TABLE 217 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 218 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 219 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 204
TABLE 220 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 204
TABLE 221 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 204
10.6.2.2 United Arab Emirates (UAE) 205
10.6.2.2.1 Growing focus on automation of platforms to fuel market 205
TABLE 222 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 205
TABLE 223 UNITED ARAB EMIRATES: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 224 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 206
TABLE 225 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 206
TABLE 226 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 207
10.6.2.3 Other GCC Countries 207
TABLE 227 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 207
TABLE 228 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 229 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 208
TABLE 230 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 209
TABLE 231 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 209
10.6.2.4 Rest of the Middle East 209
TABLE 232 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 210
TABLE 233 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION) 210
TABLE 234 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 210
TABLE 235 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 211
TABLE 236 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 211
10.7 AFRICA 211
10.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 211
TABLE 237 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 238 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 239 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022–2029 (USD MILLION) 213
TABLE 240 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022–2029 (USD MILLION) 213
TABLE 241 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022–2029 (USD MILLION) 213
10.7.2 AFRICA: RECESSION IMPACT 214
11 COMPETITIVE LANDSCAPE 215
11.1 OVERVIEW 215
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 215
FIGURE 33 STRATEGIES ADOPTED BY KEY PLAYERS 216
11.3 REVENUE ANALYSIS 217
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS, 2021−2023 217
11.4 MARKET SHARE ANALYSIS 218
FIGURE 35 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES: MARKET SHARE ANALYSIS, 2023 (TOP 3 PLAYERS) 218
TABLE 242 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DEGREE OF COMPETITION 218
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 219
11.5.1 STARS 220
11.5.2 EMERGING LEADERS 220
11.5.3 PERVASIVE PLAYERS 220
11.5.4 PARTICIPANTS 220
FIGURE 36 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 221
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 222
11.5.5.1 Company footprint 222
FIGURE 37 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: COMPANY FOOTPRINT 222
11.5.5.2 Region footprint 223
TABLE 243 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: REGION FOOTPRINT 223
11.5.5.3 Type footprint 224
TABLE 244 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: TYPE FOOTPRINT 224
11.5.5.4 Source footprint 225
TABLE 245 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: SOURCE FOOTPRINT 225
11.5.5.5 Indication footprint 226
TABLE 246 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: INDICATION FOOTPRINT 226
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023 227
11.6.1 PROGRESSIVE COMPANIES 227
11.6.2 RESPONSIVE COMPANIES 227
11.6.3 DYNAMIC COMPANIES 227
11.6.4 STARTING BLOCKS 227
FIGURE 38 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023 228
11.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023 229
TABLE 247 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DETAILED LIST OF KEY START-UPS/SMES 229
FIGURE 39 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: OVERALL FOOTPRINT FOR START-UPS/SMES 230
TABLE 248 AUTOLOGOUS STEM-CELL & NON-STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES 231
11.7 COMPANY VALUATION & FINANCIAL METRICS 232
FIGURE 40 EV/EBITDA OF KEY VENDORS 232
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 232
11.8 BRAND/PRODUCT COMPARISON 233
TABLE 249 BRAND/PRODUCT COMPARISON FOR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES (APPROVED THERAPIES) 233
11.8.1 GILEAD SCIENCES, INC. 233
11.8.2 BRISTOL-MYERS SQUIBB COMPANY 233
11.8.3 NOVARTIS AG 234
11.9 COMPETITIVE SCENARIO 234
11.9.1 PRODUCT LAUNCHES & APPROVALS 234
TABLE 250 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2024 234
11.9.2 DEALS 238
TABLE 251 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DEALS, JANUARY 2021–MAY 2024 238
TABLE 252 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: EXPANSIONS, JANUARY 2021–MAY 2024 243
11.9.3 OTHER DEVELOPMENTS 244
TABLE 253 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024 244
12 COMPANY PROFILES 245
12.1 KEY PLAYERS 245
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 BRISTOL-MYERS SQUIBB COMPANY 245
TABLE 254 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW 245
FIGURE 42 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023) 246
TABLE 255 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED 246
TABLE 256 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS, JANUARY 2021−MAY 2024 247
TABLE 257 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021− MAY 2024 248
12.1.2 GILEAD SCIENCES, INC. 250
TABLE 258 GILEAD SCIENCES, INC.: COMPANY OVERVIEW 250
FIGURE 43 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023) 251
TABLE 259 GILEAD SCIENCES, INC.: PRODUCTS OFFERED 251
TABLE 260 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2024 252
TABLE 261 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021−MAY 2024 253
TABLE 262 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024 254
12.1.3 NOVARTIS AG 255
TABLE 263 NOVARTIS AG: COMPANY OVERVIEW 255
FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT 256
TABLE 264 NOVARTIS AG: PRODUCTS OFFERED 256
TABLE 265 NOVARTIS AG: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021−MAY 2024 257
TABLE 266 NOVARTIS AG: EXPANSIONS, JANUARY 2021−MAY 2024 257
TABLE 267 NOVARTIS AG: OTHER DEVELOPMENTS, JANUARY 2021−MAY 2024 258
12.1.4 JOHNSON & JOHNSON 259
TABLE 268 JOHNSON & JOHNSON: COMPANY OVERVIEW 259
FIGURE 45 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2023) 260
TABLE 269 JOHNSON & JOHNSON: PRODUCTS OFFERED 260
TABLE 270 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2021−MAY 2024 261
TABLE 271 JOHNSON & JOHNSON: DEALS, JANUARY 2021−MAY 2024 261
12.1.5 VERICEL CORPORATION 262
TABLE 272 VERICEL CORPORATION: COMPANY OVERVIEW 262
FIGURE 46 VERICEL CORPORATION: COMPANY SNAPSHOT (2023) 263
TABLE 273 VERICEL CORPORATION: PRODUCTS OFFERED 263
TABLE 274 VERICEL CORPORATION: EXPANSIONS, JANUARY 2021−MAY 2024 264
12.1.6 IOVANCE BIOTHERAPEUTICS, INC. 265
TABLE 275 IOVANCE BIOTHERAPEUTICS, INC.: COMPANY OVERVIEW 265
FIGURE 47 IOVANCE BIOTHERAPEUTICS, INC.: COMPANY SNAPSHOT (2023) 265
TABLE 276 IOVANCE BIOTHERAPEUTICS, INC.: PRODUCTS OFFERED 266
TABLE 277 IOVANCE BIOTHERAPEUTICS, INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2024 266
TABLE 278 IOVANCE BIOTHERAPEUTICS, INC.: EXPANSIONS, JANUARY 2021−MAY 2024 266
12.1.7 JW (CAYMAN) THERAPEUTICS CO. LTD 267
TABLE 279 JW (CAYMAN) THERAPEUTICS CO. LTD: COMPANY OVERVIEW 267
FIGURE 48 JW (CAYMAN) THERAPEUTICS CO. LTD: COMPANY SNAPSHOT (2023) 267
TABLE 280 JW (CAYMAN) THERAPEUTICS CO. LTD: PRODUCTS OFFERED 268
TABLE 281 JW (CAYMAN) THERAPEUTICS CO. LTD: PRODUCT APPROVALS, JANUARY 2021−MAY 2024 268
TABLE 282 JW (CAYMAN) THERAPEUTICS CO. LTD: DEALS 269
12.1.8 PHARMICELL CO., LTD. 270
TABLE 283 PHARMICELL CO., LTD.: COMPANY OVERVIEW 270
TABLE 284 PHARMICELL CO., LTD: PRODUCTS OFFERED 270
12.1.9 HOLOSTEM S.R.L. 271
TABLE 285 HOLOSTEM S.R.L.: COMPANY OVERVIEW 271
TABLE 286 HOLOSTEM SRL: PRODUCTS OFFERED 271
12.1.10 HEALIVA SA 272
TABLE 287 HEALIVA SA: COMPANY OVERVIEW 272
TABLE 288 HEALIVA SA: PRODUCTS OFFERED 272
TABLE 289 HEALIVA SA: DEALS 273
12.1.11 APAC BIOTECH 274
TABLE 290 APAC BIOTECH: COMPANY OVERVIEW 274
TABLE 291 APAC BIOTECH: PRODUCTS OFFERED 274
12.1.12 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT) 275
TABLE 292 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: COMPANY OVERVIEW 275
TABLE 293 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: PRODUCTS OFFERED 275
TABLE 294 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: DEALS 276
TABLE 295 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024 277
12.1.13 REGROW BIOSCIENCES PVT LTD. 278
TABLE 296 REGROW BIOSCIENCES PVT LTD.: COMPANY OVERVIEW 278
TABLE 297 REGROW BIOSCIENCES PVT LTD.: PRODUCTS OFFERED 278
TABLE 298 REGROW BIOSCIENCES PVT LTD.: PRODUCT APPROVALS, JANUARY 2021−MAY 2024 279
12.1.14 TEGO SCIENCE, INC. 280
TABLE 299 TEGO SCIENCE, INC.: COMPANY OVERVIEW 280
TABLE 300 TEGO SCIENCE, INC.: PRODUCTS OFFERED 281
12.1.15 CARSGEN THERAPEUTICS HOLDINGS LIMITED 282
TABLE 301 CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY OVERVIEW 282
TABLE 302 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCTS OFFERED 283
TABLE 303 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCT APPROVALS, JANUARY 2021−MAY 2024 284
TABLE 304 CARSGEN THERAPEUTICS HOLDINGS LIMITED: EXPANSIONS 285
TABLE 305 CARSGEN THERAPEUTICS HOLDINGS LIMITED: DEALS 285
12.1.16 IASO BIOTHERAPEUTICS 286
TABLE 306 IASO BIOTHERAPEUTICS: COMPANY OVERVIEW 286
TABLE 307 IASO BIOTHERAPEUTICS: PRODUCTS OFFERED 286
TABLE 308 IASO BIOTHERAPEUTICS: PRODUCT APPROVALS 287
TABLE 309 IASO BIOTHERAPEUTICS: DEALS 288
12.1.17 ANTEROGEN.CO.,LTD. 289
TABLE 310 ANTEROGEN.CO.,LTD.: COMPANY OVERVIEW 289
TABLE 311 ANTEROGEN.CO.,LTD.: PRODUCTS OFFERED 289
12.1.18 GREEN CROSS HOLDINGS CO., LTD. (GC CELL) 290
TABLE 312 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): COMPANY OVERVIEW 290
FIGURE 49 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): COMPANY OVERVIEW (2023) 290
TABLE 313 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): PRODUCTS OFFERED 291
TABLE 314 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): DEALS 291
12.1.19 SANPOWER GROUP CO., LTD. (DENDREON PHARMACEUTICALS LLC.) 292
TABLE 315 SANPOWER GROUP CO., LTD.: COMPANY OVERVIEW 292
TABLE 316 SANPOWER GROUP CO., LTD. (DENDREON): PRODUCTS OFFERED 292
12.2 OTHER PLAYERS 293
12.2.1 PROKIDNEY CORP. 293
TABLE 317 PROKIDNEY CORP.: COMPANY OVERVIEW 293
12.2.2 BIOCARDIA, INC. 294
TABLE 318 BIOCARDIA, INC.: COMPANY OVERVIEW 294
12.2.3 NEUROPLAST B.V. 295
TABLE 319 NEUROPLAST B.V.: COMPANY OVERVIEW 295
12.2.4 ADAPTIMMUNE THERAPEUTICS PLC 296
TABLE 320 ADAPTIMMUNE THERAPEUTICS PLC.: COMPANY OVERVIEW 296
12.2.5 AGONOX, INC. 297
TABLE 321 AGONIX, INC.: COMPANY OVERVIEW 297
12.2.6 KYVERNA THERAPEUTICS, INC. 298
TABLE 322 KYVERNA THERAPEUTICS, INC.: COMPANY OVERVIEW 298
12.2.7 OBSIDIAN THERAPEUTICS, INC. 299
TABLE 323 OBSIDIAN THERAPEUTICS, INC.: COMPANY OVERVIEW 299
12.2.8 AVOTRES INC. 300
TABLE 324 AVOTRES, INC.: COMPANY OVERVIEW 300
12.2.9 CORESTEMCHEMON INC. 301
TABLE 325 CORESTEMCHEMON INC.: COMPANY OVERVIEW 301
12.2.10 JUVENTAS CELL THERAPY LTD. 302
TABLE 326 JUVENTAS CELL THERAPY LTD.: COMPANY OVERVIEW 302
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 303
13.1 DISCUSSION GUIDE 303
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 306
13.3 CUSTOMIZATION OPTIONS 308
13.4 RELATED REPORTS 308
13.5 AUTHOR DETAILS 309
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11